43 results about "CDK4 Inhibitor" patented technology

The present application provides compounds of Formula (I):or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 4 (CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Various salt forms and free bases of compound (I) represented by the following chemical formula are disclosed (I).

Disclosed herein are bicyclic compound derivatives used as inhibitors of cyclin-dependent kinases. Disclosed herein is the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of such compounds for treating cancer.

Provided herein are CDK inhibitor compounds having a fused 6-6 bicyclic heteroaryl core, such as naphthyridine, quinazoline, pyridopyrimidine or a further substituted associated electron isosteric core structure. The core structure may be substituted with an amino group, wherein the amino group is further substituted with a cyclic group having an additional hydrophilic group. Also provided herein are compositions comprising the subject CDK inhibitor compounds. In some embodiments, the CDK inhibitor compound is a CDK2 inhibitor or a CDK4 inhibitor. Methods of using the compositions of the present disclosure in research or as therapeutic agents are also provided.

The present application provides compounds of Formula (I):or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 4 (CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

The application provides a polymorph of a compound of formula (A) (N-(1-((4-((3S,5S)-3,5-dimethylpiperazin-1-yl)phenyl)sulfonyl)piperidin-4-yl)-4-((S)-tetrahydrofuran-3-yl)oxy)-5-(trifluoromethyl)pyrimidin-2-amine) and a polymorph of a phosphate salt of the compound of formula (A). The crystal form provided by the application has good chemical stability, physical stability and low hygroscopicity, is less affected by temperature, humidity and light, and is convenient to store and develop into a preparation.

Provided herein are methods of treating diseases, disorders, or conditions including cancers, where the methods comprise administration of Compound 1, or a pharmaceutically acceptable salt thereof, in combination with a CDK inhibitor or a selective estrogen receptor degrader (SERB), as described herein. Such methods may comprise the treatment of cancer, such as breast cancer.

Disclosed herein are bicyclic compound derivatives useful as cyclin dependent kinase inhibitors. Disclosed herein are the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of these compounds for the treatment of cancer.

Disclosed herein are compounds used as inhibitors of cyclin-dependent kinases. Disclosed herein is the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of such compounds for treating cancer.

Disclosed are various salt forms and the free base of Compound (I) represented by the following formula. (I).

This invention relates to, in part, a method for treating cancer by administering a CDK4 inhibitor in combination with a PD-1 axis binding antagonist, and optionally an CDK2 inhibitor to a subject in need thereof.

This invention relates to crystalline and amorphous forms of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol, to pharmaceutical compositions comprising such solid forms, and to use of such solid forms and pharmaceutical compositions for the treatment of cancer.

The present application provides compounds of Formula (I):or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 2 and 4 (CDK2 and CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Provided herein are CDK inhibitors, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provide herein is a method of their use for treating, preventing, or ameliorating a chemotherapy-induced gastrointestinal side effect.

strutural formula: F N N N N N N N N N cancer. 20 26 20 09 99 11 F eb 2 02 6 A B S T R A C T 2 0 2 6 2 0 0 9 9 9 1 1 F e b 2 0 2 6 F N N N N N N N N c a n c e r . A B S T R A C T 2 0 2 6 2 0 0 9 9 9 1 1 F e b 2 0 2 6 F N N N N N N N N c a n c e r .

The disclosure is in part directed to crystalline forms of (3R,5R)-5-(5-(3-(2,2-difluoroethoxy)-1-methyl-1H-pyrazole-5-carboxamido)-1H-pyrazol-3-yl)tetrahydrofuran-3-yl bicyclo[1.1.1]pentan-1-ylcarbamate, its solvates, its cocrystals, and variants thereof.

This disclosure relates to combination therapies comprising a cyclin dependent kinase 4 (CDK4) inhibitor of Formula (I) disclosed herein, and a monoclonal antibody or an antibody-drug conjugate, optionally in further combination with an endocrine therapy agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.

The invention relates to a method for improving the infection efficiency of AAV (adeno-associated virus) infected cells, which comprises the following steps: the cells to be infected are contacted with a DNA replication inhibitor, and the DNA replication inhibitor comprises a cell cycle non-specific drug and / or a CDK inhibitor. According to the method disclosed by the invention, the infection efficiency of the AAV infected cells can be remarkably improved.

Provided are a pharmaceutical combination and a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable form thereof and at least one other anticancer agent, and use thereof in the preparation of a medicine for treating a malignant tumor disease. The other anticancer agent is a CDK inhibitor or a pharmaceutically acceptable salt thereof (such as palbociclib), lenvatinib or a pharmaceutically acceptable salt thereof, sorafenib or a pharmaceutically acceptable salt thereof, or any combination of the above.

The present invention relates to compounds of formula (I) as inhibitors of cyclin-dependent kinase 4 (CDK4) for use in methods of treatment of cancer.

Provided herein are certain aminoheteroaryl compounds with tricyclic structure moiety, pharmaceutical compositions, and methods of use related to cyclin dependent kinases (CDKs). The compounds provided herein are typically CDK4 inhibitors, which can be used for treating a variety of diseases or disorders, such as cancer.

The present invention provides a pharmaceutical comprising a HER2 inhibitor or a CDK inhibitor that inhibits CDK4 and / or CDK6. The present invention further provides the use of a HER2 inhibitor in combination with a CDK inhibitor for treating tumors, and their use in preparing a medicament for treating tumors. The combination of the present invention significantly enhances tumor inhibition.

The present invention relates to a method of determining the therapy for treating a subject afflicted from breast cancer comprising determining the P27 T2871099G SNP in a sample of said subject and administering only endocrine therapy if the polymorphism is other than T2871099G, and administering endocrine therapy in combination with at least one CDK4 / 6 inhibitor if the polymorphism is homozygous T2871099G.

The present invention relates to a CDK kinase inhibitor and its pharmaceutical use. In particular, the present invention relates to a CDK inhibitor having the structure of formula (I) and its pharmaceutical composition, and its use as a CDK inhibitor and its use in the manufacture of a medicament for treating a cancer or a tumor at least partially associated with CDK. Wherein each substituent of formula (I) is the same as defined in the specification.

Provided herein are methods related to detecting rearrangements in the B-cell lymphoma 6 (BCL6) corepressor (BCOR) or BCL6 corepressor-like protein I (BCORL1) gene, as well as methods of treatment, uses, and kits related thereto. As demonstrated herein, detection of BCOR rearrangements can be used to identify individuals that may benefit from treatment with a targeted therapeutic, such as a CDK inhibitor, an MDM2 inhibitor, a tyrosine kinase inhibitor, a MEK inhibitor, an mTOR inhibitor, or a Hh inhibitor. In some embodiments, the BCOR rearrangement is a fusion gene between BCOR and L3MBTL2, EP300, NUTM2G, MAP7D2, RALGPS1 RGAG1, CREBBP, ING3, NUGGC, or KMT 2D.